Post A Reply
Allstocks.com's Bulletin Board
Hot Stocks Free for All !
GALE Galena Biopharma Inc.
» Post A Reply
Post A Reply
HTML is not enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by BooDog: [QB] Last Change / % Change Dividend Yield Volume Avg Volume (10 day) S&P Capital IQ Ranking 6.24 0.88 16.42% 0.00% 25,428,843 6.2M No Ranking Add to Watch ListSet Alert Education help is OFF Market data is in Real-time. Summary News Charts Options Fundamentals Insiders Earnings Financials SEC Filings Summary chart showing the current equity's performance of over the past 1 daysMACDVolume EMA (20) Advanced Charts Embed Chart 1 Day 5 Day 6 Mo 1 Yr 5 Yr Market is closed. As of 04:00 PM ET 1/8/2014 Latest News Headlines for Galena Biopharma Inc Galena Biopharma Enrolls First Patient In GALE-301 (Folate Binding Protein (FBP)) Cancer Immunotherapy Phase 2 Clinical Trial In Ovarian Cancer1 days 11 hours 39 minutes ago - Dow Jones News Dow Jones News has only provided a headline at this time. Galena Biopharma Enrolls First Patient in GALE-301 (Folate Binding Protein (FBP)) Cancer Immunotherapy Phase 2 Clinical Trial in Ovarian Cancer1 days 11 hours 39 minutes ago - GlobeNewsWire via Dow Jones News Galena Biopharma Enrolls First Patient in GALE-301 (Folate Binding Protein (FBP)) Cancer Immunotherapy Phase 2 Clinical Trial in Ovarian Cancer PORTLAND, Ore., Jan. 7, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced the first patient has been enrolled in the Phase 2 trial for GALE-301 (Folate Binding Protein (FBP) vaccine). GALE-301 is a folate receptor alpha-derived, peptide-based cancer immunotherapy administered to HLA-A2 positive patients in combination with granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjuvant treatment to prevent recurrences in high-risk, endometrial and ovarian cancer patients rendered disease-free after completing standard of care therapy. View more recent headlines Latest Annual and Quarterly SEC Filings More Filings 10-KMarch 12, 2013 This report contains detailed information about the company's business finances and management. 10-QNovember 6, 2013 Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.) Company Background Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). The Company's Phase 2 trial of NeuVax achieved its primary endpoint of disease-free survival (DFS). On April 13, 2011, the Company completed its acquisition of Apthera, Inc.,(Apthera). http://www.galenabiopharma.com/ Bid/Size Ask/Size 6.26 / 100 6.28 / 700 Price Open Previous Close 5.52 5.36 Day High Day Low 6.84 5.50 [/QB][/QUOTE]
Instant UBB Code™
What is UBB Code™?
Disable Graemlins in this post.
*** Click here to review this topic. ***
Allstocks.com Message Board Home
© 1997 - 2013 Allstocks.com. All rights reserved.